Xenetic Biosciences, Inc. ( (XBIO) ) has released its Q2 earnings. Here is a breakdown of the information Xenetic Biosciences, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xenetic Biosciences, Inc., a biopharmaceutical company based in Framingham, Massachusetts, focuses on advancing innovative immune-oncology technologies to address hard-to-treat cancers. The company’s proprietary DNase technology aims to improve cancer treatment outcomes by targeting neutrophil extracellular traps involved in cancer progression. In its latest earnings report for the quarter ended June 30, 2025, Xenetic reported a decrease in revenue and a reduced net loss compared to the same period in 2024. The company recorded a net loss of approximately $688,703, a significant improvement from the $1.27 million loss in the previous year. Revenue from royalty agreements decreased by 18.8% to $589,897, primarily due to timing differences in rebates from its sublicense agreement with Takeda Pharmaceuticals. Operating expenses also saw a decline, with research and development expenses down by 29.7% and general and administrative expenses reduced by 41.8%, contributing to the overall improved financial performance. Looking ahead, Xenetic remains focused on advancing its DNase technology into clinical trials as an adjunctive therapy for pancreatic carcinoma and other solid tumors. The company acknowledges the need for additional capital to pursue its long-term business initiatives and remains optimistic about securing necessary resources through various financing avenues.